REFERENCES
1. Huang S, Cao L, Cheng H, Li D, Li Y, Wu Z. The blooming intersection of subfatin and metabolic syndrome. Rev Cardiovasc Med. 2021;22:799-805.
2. Li ZY, Song J, Zheng SL, et al. Adipocyte metrnl antagonizes insulin resistance through PPARγ signaling. Diabetes. 2015;64:4011-22.
3. Dong WS, Hu C, Hu M, et al. Metrnl: a promising biomarker and therapeutic target for cardiovascular and metabolic diseases. Cell Commun Signal. 2024;22:389.
4. Nishino J, Yamashita K, Hashiguchi H, Fujii H, Shimazaki T, Hamada H. Meteorin: a secreted protein that regulates glial cell differentiation and promotes axonal extension. EMBO J. 2004;23:1998-2008.
5. Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157:1279-91.
6. Jørgensen JR, Fransson A, Fjord-Larsen L, et al. Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo. Exp Neurol. 2012;233:172-81.
7. Li ZY, Zheng SL, Wang P, et al. Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression. CNS Neurosci Ther. 2014;20:344-54.
8. Jung TW, Lee SH, Kim HC, et al. METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPARδ-dependent pathways in skeletal muscle of mice. Exp Mol Med. 2018;50:1-11.
9. Miao ZW, Hu WJ, Li ZY, Miao CY. Involvement of the secreted protein Metrnl in human diseases. Acta Pharmacol Sin. 2020;41:1525-30.
10. Jackson CM, Pant A, Dinalankara W, et al. The cytokine Meteorin-like inhibits anti-tumor CD8+ T cell responses by disrupting mitochondrial function. Immunity. 2024;57:1864-77.e9.
11. Liu N, Dong J, Li L, Zhou D, Liu F. The function and mechanism of anti-inflammatory factor Metrnl prevents the progression of inflammatory-mediated pathological bone osteolytic diseases. J Inflamm Res. 2024;17:1607-19.
12. Jørgensen JR, Thompson L, Fjord-Larsen L, et al. Characterization of Meteorin-an evolutionary conserved neurotrophic factor. J Mol Neurosci. 2009;39:104-16.
13. Baht GS, Bareja A, Lee DE, et al. Author correction: Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism. Nat Metab. 2020;2:794.
14. Huang D, Liu X, Gao X, et al. Meteorin-like protein/METRNL/interleukin-41 ameliorates atopic dermatitis-like inflammation. Allergy. 2024;Online ahead of print.
15. Lu QB, Ding Y, Liu Y, et al. Metrnl ameliorates diabetic cardiomyopathy via inactivation of cGAS/STING signaling dependent on LKB1/AMPK/ULK1-mediated autophagy. J Adv Res. 2023;51:161-79.
16. Zheng SL, Li ZY, Song J, Liu JM, Miao CY. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016;37:571-9.
17. Wu D, Molofsky AB, Liang HE, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 2011;332:243-7.
18. Coker RH, Weaver AN, Coker MS, Murphy CJ, Gunga HC, Steinach M. Metabolic responses to the Yukon Arctic ultra: longest and coldest in the world. Med Sci Sports Exerc. 2017;49:357-62.
19. Yan Q, Li W, Gong X, Hu R, Chen L. Transcriptomic and phenotypic analysis of CRISPR/Cas9-mediated gluk2 knockout in zebrafish. Genes. 2022;13:1441.
20. Saghebjoo M, Einaloo A, Mogharnasi M, Ahmadabadi F. The response of meteorin-like hormone and interleukin-4 in overweight women during exercise in temperate, warm and cold water. Horm Mol Biol Clin Investig. 2018;36:20180027.
21. Song L, Chang X, Hu L, et al. Accelerating wound closure with metrnl in normal and diabetic mouse skin. Diabetes. 2023;72:1692-706.
22. Yao C, Zhang H, Wang L, Li J. Correlation of serum Meteorin-like (Metrnl) level with type 2 diabetic peripheral neuropathy. BMC Endocr Disord. 2024;24:83.
23. Tayebi SM, Motaghinasab S, Eslami R, Ahmadabadi S, Basereh A, Jamhiri I. Impact of 8-week cold-and warm water swimming training combined with cinnamon consumption on serum METRNL, HDAC5, and insulin resistance levels in diabetic male rats. Heliyon. 2024;10:e29742.
24. Schmid A, Karrasch T, Schäffler A. Meteorin-like protein (Metrnl) in obesity, during weight loss and in adipocyte differentiation. J Clin Med. 2021;10:4338.
25. Onalan E, Cavlı C, Dogan Y, et al. Low serum levels of meteorin-like/subfatin: an indicator of diabetes mellitus and insulin resistance? Endokrynol Pol. 2020;71:397-403.
26. Qi Q, Hu WJ, Zheng SL, et al. Metrnl deficiency decreases blood HDL cholesterol and increases blood triglyceride. Acta Pharmacol Sin. 2020;41:1568-75.
27. Liu M, Gao X, Tian Y, et al. Serum metrnl is decreased in metabolic dysfunction-associated fatty liver disease: a case-control study. Diabetes Metab Syndr Obes. 2024;17:533-43.
28. Javaid HMA, Sahar NE, ZhuGe DL, Huh JY. Exercise inhibits NLRP3 inflammasome activation in obese mice via the anti-inflammatory effect of Meteorin-like. Cells. 2021;10:3480.
29. Moradi N, Fadaei R, Roozbehkia M, et al. Meteorin-like protein and asprosin levels in children and adolescents with obesity and their relationship with insulin resistance and metabolic syndrome. Lab Med. 2023;54:457-63.
30. Du Y, Ye X, Lu A, et al. Inverse relationship between serum Metrnl levels and visceral fat obesity (VFO) in patients with type 2 diabetes. Diabetes Res Clin Pract. 2020;161:108068.
31. Garcia-Beltran C, Navarro-Gascon A, López-Bermejo A, et al. Meteorin-like levels are associated with active brown adipose tissue in early infancy. Front Endocrinol. 2023;14:1136245.
32. Jamal MH, Abu-Farha M, Al-Khaledi G, et al. Effect of sleeve gastrectomy on the expression of meteorin-like (METRNL) and Irisin (FNDC5) in muscle and brown adipose tissue and its impact on uncoupling proteins in diet-induced obesity rats. Surg Obes Relat Dis. 2020;16:1910-8.
33. Amano Y, Nonaka Y, Takeda R, Kano Y, Hoshino D. Effects of electrical stimulation-induced resistance exercise training on white and brown adipose tissues and plasma meteorin-like concentration in rats. Physiol Rep. 2020;8:e14540.
34. Rupérez C, Ferrer-Curriu G, Cervera-Barea A, et al. Meteorin-like/Meteorin-β protects heart against cardiac dysfunction. J Exp Med. 2021;218:e20201206.
35. Ding X, Chang X, Wang J, et al. Serum Metrnl levels are decreased in subjects with overweight or obesity and are independently associated with adverse lipid profile. Front Endocrinol. 2022;13:938341.
36. Lin L, Huang S, Lin X, et al. Upregulation of Metrnl improves diabetic kidney disease by inhibiting the TGF-β1/Smads signaling pathway: a potential therapeutic target. PLoS One. 2024;19:e0309338.
37. Zheng S, Li Z, Song J, et al. Endothelial METRNL determines circulating METRNL level and maintains endothelial function against atherosclerosis. Acta Pharm Sin B. 2023;13:1568-87.
38. Wang Y, Jiang Y, Lian Y, Chen B. Correlation of serum meteorin-like protein with non-alcoholic fatty liver disease: an analysis of 183 cases. J Third Mil Med Univ 2018;40:1996-2000. (in Chinese) Available from: https://lib.cqvip.com/Qikan/Article/Detail?id=676691237&from=Qikan_Article_Detail. [Last accessed on 22 Jan 2025].
39. Garcia-Beltran C, Cereijo R, Plou C, et al. Posterior cervical brown fat and CXCL14 levels in the first year of life: sex differences and association with adiposity. J Clin Endocrinol Metab. 2022;107:e1148-58.
40. Alizadeh H. Myokine-mediated exercise effects: the role of myokine meteorin-like hormone (Metrnl). Growth Factors. 2021;39:71-8.
41. Jamal MH, AlOtaibi F, Dsouza C, et al. Changes in the expression of meteorin-like (METRNL), irisin (FNDC5), and uncoupling proteins (UCPs) after bariatric surgery. Obesity. 2022;30:1629-38.
42. Löffler D, Landgraf K, Rockstroh D, et al. METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans. Int J Obes. 2017;41:112-9.
43. Kim JE, Kim JS, Jo MJ, et al. The roles and associated mechanisms of adipokines in development of metabolic syndrome. Molecules. 2022;27:334.
44. AlKhairi I, Cherian P, Abu-Farha M, et al. Increased expression of meteorin-like hormone in type 2 diabetes and obesity and its association with irisin. Cells. 2019;8:1283.
45. Dadmanesh M, Aghajani H, Fadaei R, Ghorban K. Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS One. 2018;13:e0204180.
46. Aktas G, Kocak MZ, Bilgin S, Atak BM, Duman TT, Kurtkulagi O. Uric acid to HDL cholesterol ratio is a strong predictor of diabetic control in men with type 2 diabetes mellitus. Aging Male. 2020;23:1098-102.
47. Phuong LDT, Tran Huy T, Huynh Quang T. The plasma levels of protein adiponectin (AdipoQ) and meteorin-like (Metrnl) in newly diagnosed type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2024;17:2903-9.
48. Tok Ö, Kişioğlu SV, Ersöz HÖ, Kahveci B, Göktaş Z. Effects of increased physical activity and/or weight loss diet on serum myokine and adipokine levels in overweight adults with impaired glucose metabolism. J Diabetes Complications. 2021;35:107892.
49. Lee JO, Byun WS, Kang MJ, et al. The myokine meteorin-like (metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting AMPKα2. FEBS J. 2020;287:2087-104.
50. Wu Q, Dan YL, He YS, et al. Circulating meteorin-like levels in patients with type 2 diabetes mellitus: a meta-analysis. Curr Pharm Des. 2020;26:5732-8.
51. Tuncer Kara K, Kizil M, Çakmak E, et al. Comparison of plasma and salivary meteorin-like protein levels in patients with newly diagnosed type-2 diabetes and treated with metformin. Eur Rev Med Pharmacol Sci. 2022;26:7145-50.
52. Cheng JX, Yu K. New discovered adipokines associated with the pathogenesis of obesity and type 2 diabetes. Diabetes Metab Syndr Obes. 2022;15:2381-9.
53. Khajebishak Y, Faghfouri AH, Soleimani A, Madani S, Payahoo L. Exploration of meteorin-like peptide (Metrnl) predictors in type 2 diabetic patients: the potential role of irisin, and other biochemical parameters. Horm Mol Biol Clin Investig. 2023;44:127-35.
54. Liu ZX, Ji HH, Yao MP, et al. Serum Metrnl is associated with the presence and severity of coronary artery disease. J Cell Mol Med. 2019;23:271-80.
55. Ferns GA, Fekri K, Shahini Shams Abadi M, Banitalebi Dehkordi M, Arjmand MH. A meta-analysis of the relationship between serums metrnl-like protein/subfatin and risk of type 2 diabetes mellitus and coronary artery disease. Arch Physiol Biochem. 2023;129:1084-90.
56. Jung TW, Pyun DH, Kim TJ, et al. Meteorin-like protein (METRNL)/IL-41 improves LPS-induced inflammatory responses via AMPK or PPARδ-mediated signaling pathways. Adv Med Sci. 2021;66:155-61.
57. Wang R, Hu D, Zhao X, Hu W. Correlation of serum meteorin-like concentrations with diabetic nephropathy. Diabetes Res Clin Pract. 2020;169:108443.
58. Lappas M. Maternal obesity and gestational diabetes decrease Metrnl concentrations in cord plasma. J Matern Fetal Neonatal Med. 2021;34:2991-5.
59. Miao CY. Introduction: adipokines and cardiovascular disease. Clin Exp Pharmacol Physiol. 2011;38:860-3.
60. El-Ashmawy HM, Selim FO, Hosny TAM, Almassry HN. Association of low serum Meteorin like (Metrnl) concentrations with worsening of glucose tolerance, impaired endothelial function and atherosclerosis. Diabetes Res Clin Pract. 2019;150:57-63.
61. Basa ML, Cha DS, Mitchell DP, Chan DL. Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review. Metab Target Organ Damage. 2024;4:29.
62. Grander C, Grabherr F, Enrich B, et al. Hepatic Meteorin-like and Krüppel-like factor 3 are associated with weight loss and liver injury. Exp Clin Endocrinol Diabetes. 2022;130:406-14.
63. Boutari C, Tziomalos K, Athyros VG. The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease. Hippokratia. 2016;20:259-63.
64. Polyzos SA, Kountouras J, Papatheodorou A, et al. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: introduction of CHA index. Ann Hepatol. 2013;12:749-57.
65. Du YN, Teng JM, Zhou TH, Du BY, Cai W. Meteorin-like protein overexpression ameliorates fulminant hepatitis in mice by inhibiting chemokine-dependent immune cell infiltration. Acta Pharmacol Sin. 2023;44:1404-15.
